

Questionnaire for Feb

**International Stem Cell Banking Initiative**

**Clinical Grade Stem Cell Lines Workshop Questionnaire, Feb 2008**

NB you may have already supplied some of this information for the ISCF website – there is no need to resubmit this information if this is the case

Section 1 : details of supplier of questionnaire response

Name of correspondent submitting questionnaire **Dong-Wook Kim**

Contact details ..... **dwkim2@yuhs.ac**

Name of Organisation .... **...Korean Stem Cell Bank**

Address

**Stem Cell Research Center,**

**Old Out-patient Clinic Building B1, Yonsei University Medical Center,**

**134 Shinchon-dong, Seodaemun-gu, Seoul 120-752, Korea.....**

Section 2. National Regulations

A National regulatory bodies dealing with:

1) Stem cell ethics (include website or other address)

**Bioethic & Safety Team, Office of Health Industry Promotion, Ministry of Health and Welfare**

88 Gwanmullo, Jungang-dong, Gwacheon-si, Gyeonggi-do, 427-721,  
Republic of Korea

Tel +82-31-440-9144

Web site : [www.mohw.go.kr](http://www.mohw.go.kr)

2) Clinical application of stem cells (include website or other address)

**At present, clinical grade of human ES cell are derived in CHA Stem Cell Institute.**

(Contact details)...**Dong Ryul Lee, Ph.D., E-mail) drleedr@cha.ac.kr**

**Hyung Min Chung, Ph.D., E-mail) stem\_chung@naver.com**

**CHA Stem Cell Institute, Pochon CHA University College of Medicine, Seoul,  
Korea**

**606-5 Yeoksam-dong, Gangnam-gu, Seoul 135-081, Korea.....**

B) Local use of stem cells

Types of cells used

Are cells provided for clinical treatment .....**Not Yet**.....

Is the bank accredited for supply of cells for therapy ..... **Not Yet** .....

Brief description of current work (attach additional information if appropriate)

.....

**CHA Stem Cell Institute : Establishing clinical-grade hESs lines more than 100 lines**

Plans for future work.....

**CHA Stem Cell Institute : Establishing clinical-grade hESs lines more than 100 lines and characterization.....**

3) Issues for discussion

Are you generally happy with the content and balance of the proposed workshop?

**Yes**

Would you like more background information on any aspects of the topics for discussion? **No**

Are there any technical issues not covered in the current programme that should be included or need more time than allocated already? **No**

From your own countries perspective or those of other countries do you feel there are any cultural issues that may impact on the delivery of therapies given that tissues from a diverse range of individuals and species may be used in the preparation of therapies in different countries? **No**

Are there any other organisations in your country that you feel should be involved and why? **No**

What is your greatest concern regarding the delivery of clinical grade stem cell lines? **No**

What do you perceive as the greatest barrier to delivery of therapies based on the use of clinical grade stem cell lines?

How do you believe different countries could harmonise approaches to regulation for delivery of therapies and also how your regulatory body could interact within the international community?

Please highlight any information you do NOT wish to be entered on the ISCF website.